News

The rheumatology month in review emphasizes new approvals and best-in-class efficacy data.

The FDA has approved the therapy, marketed as Wayrilz, a new treatment for chronic immune thrombocytopenia.

Regeneron is planning a BLA submission for the first quarter of 2026.

This FDA News Month in Review provides a round-up of regulatory decisions from August 2025.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

Despite high cardiovascular risk with the 2 comorbidities, no beneficial effect was seen with colchicine.

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

A recent study reveals gout patients face higher chronic opioid prescription rates.

Rosnilimab shows promising long-term efficacy in treating moderate-to-severe rheumatoid arthritis.

Allopurinol and febuxostat, recently associated with significant risk of macrovascular disorders, have no increased risk of microvascular conditions.

DRESS-PS extension study shows patients maintaining low disease activity while gradually reducing TNF inhibitor doses over 24 months.

The therapy, marketed as Tonmya, is a sublingual formulation of cyclobenzaprine HCl.

Findings from the prospective feasibility study support further evaluation of the 6-week home-based stretching program in a randomized controlled trial.

Using an established full and simplified definition, investigators found a substantial percentage of the MIRROR population achieved gout remission.

Sarilumab 200 mg every 2 weeks with a 14-week glucocorticoid taper significantly boosted patient-reported outcomes versus placebo in polymyalgia rheumatica.

Targeting changes in foot progression angle to maximally reduce knee loading led to greater reductions in medial knee pain and knee adduction moment peak.

SetPoint Medical's FDA-approved device offers a new neuroimmune therapy for rheumatoid arthritis, enhancing treatment options without immune risks.

Novartis is planning regulatory submissions for the therapy, which could become the first to meaningfully modify disease activity.

New research reveals challenges in maintaining urate-lowering therapy for gout, highlighting disparities in adherence among diverse patient populations.

The APEX study presents the results of 2 dosing regimens of guselkumab (Q4W and Q8W) in biologic-naïve patients with psoriatic arthritis (PsA).

New findings reveal CFT outperformed usual care to significantly reduce chronic low back pain and activity limitations.

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

This session at the DERM 2025 conference highlights several clinical pearls in dermatology and was presented by rheumatologist Karim Ladak, MD.

Guselkumab shows promise as the first IL-23 inhibitor to significantly reduce joint damage in active psoriatic arthritis.

Reformer Pilates significantly reduces pain and enhances mental and physical health in women with chronic musculoskeletal pain, promoting active living and coping strategies.

New phase 3 trials reveal tildrakizumab 100mg significantly improves symptoms in active psoriatic arthritis, offering hope for effective treatment options.

Virtual cognitive behavioral therapy delivered via phone or online led to moderate improvements in pain and function in the phase 3 RESOLVE trial.

Machine learning uncovers gut microbiome biomarkers linked to purine metabolism, enhancing diagnostic strategies for gout and hyperuricemia.